MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Core Viewpoint - MediciNova, Inc. is set to present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference, highlighting its clinical-stage biopharmaceutical developments and pipeline [1][3]. Company Overview - MediciNova, Inc. is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases [3]. - The company has a late-stage pipeline that includes 11 clinical programs based on two main compounds: MN-166 (ibudilast) and MN-001 (tipelukast) [3]. Clinical Development - MN-166 (ibudilast) is currently in Phase 3 trials for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM), and is ready for Phase 3 for progressive multiple sclerosis (MS) [3]. - MN-166 is also being evaluated in Phase 2 trials for Long COVID and substance dependence [3]. - MN-001 (tipelukast) has been evaluated in a Phase 2 trial for idiopathic pulmonary fibrosis (IPF), with an ongoing Phase 2 trial for non-alcoholic fatty liver disease (NAFLD) [3]. Conference Details - The presentation will be available on-demand starting at 7:00 am ET on September 5, 2025, and a live webcast can be accessed through the investor relations section of the MediciNova website [2][3]. - Drs. Iwaki and Crean will be available for one-on-one meetings throughout the conference [3].